Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
2002 1
2004 2
2006 1
2007 4
2008 4
2009 1
2011 3
2012 2
2016 1
2017 2
2019 1
2022 1
2023 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis.
Fernández-Ávila DG, Bautista-Molano W, Brance ML, Ávila Pedretti MG, Vargas RB, Díaz Coto JF, Gutiérrez LA, Gutiérrez M, Ho EG, Ibáñez Vodnizza SE, Jáuregui E, Ocampo V, Palominos PE, Palleiro Rivero DR, Quiceno GA, Sommerfleck FA, Vega Espinoza LE, Hinojosa OV, Barrezueta CV, Corbacho I, Cosentino VL, Sariego AG, Resende GG, Saldarriaga-Rivera LM, Pacheco Tena CF, Citera G, Lozada C, Ranza R, Sampaio-Barros PD, Schneeberger E, Soriano ER; Pan American League of Associations for Rheumatology (PANLAR). Fernández-Ávila DG, et al. Among authors: vargas rb. J Rheumatol. 2024 Jun 1;51(6):563-576. doi: 10.3899/jrheum.2023-1172. J Rheumatol. 2024. PMID: 38561190 Free article.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD.
Norris KC, Duru OK, Alicic RZ, Daratha KB, Nicholas SB, McPherson SM, Bell DS, Shen JI, Jones CR, Moin T, Waterman AD, Neumiller JJ, Vargas RB, Bui AAT, Mangione CM, Tuttle KR; CURE-CKD investigators. Norris KC, et al. Among authors: vargas rb. BMC Nephrol. 2019 Nov 20;20(1):416. doi: 10.1186/s12882-019-1558-9. BMC Nephrol. 2019. PMID: 31747918 Free PMC article.
24 results